Mauna Kea Technologies (Euronext: MKEA) inventor of Cellvizio®, the multidisciplinary probe-based and needle-based confocal laser endomicroscopy (pCLE/ nCLE ) platform…
Mauna Kea Technologies (Euronext: MKEA) inventor of Cellvizio®, the multidisciplinary probe-based and needle-based confocal laser endomicroscopy (pCLE/ nCLE ) platform…
Mauna Kea Technologies (Euronext: MKEA) inventor of Cellvizio®, the multidisciplinary probe-based and needle-based confocal laser endomicroscopy (pCLE/ nCLE ) platform…
Mauna Kea Technologies (Euronext: MKEA) inventor of Cellvizio®, the multidisciplinary probe-based and needle-based confocal laser endomicroscopy (pCLE/ nCLE ) platform…
Mauna Kea Technologies (Euronext: MKEA) inventor of Cellvizio®, the multidisciplinary probe-based and needle-based confocal laser endomicroscopy (pCLE/ nCLE ) platform…
Sale of Oncimmune Limited to Freenome Oncimmune Holdings plc, the leading global immunodiagnostics group, today announces that it has sold its wholly-owned subsidiaries, Oncimmune Limited (including the CEmarked IVD EarlyCDT® Lung blood test, antibody platform and research and development pipeline) and Oncimmune Europe GmbH to Freenome Holdings, Inc. for a total of £13M in cash.…
IPF Partners Closes a Debt Financing with Patient21, as Part of its €100M Series C Patient21, a four-year-old German startup that combines a digital healthcare platform with real-world brick-and-mortar clinics, has raised €100 million ($108 million) in a Series C round of funding led by Israeli VC firm Pitango, constituting a mix of equity and…
Poxel Announces Cash Runway Extended Through Q2 2025 Based upon Debt Restructuring Agreement and New Equity-linked Financing Facility Poxel SA, a clinical stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, announced today that is has finalized (1) agreements with its lenders to…
Poxel Reports Cash and Revenue for the Full Year 2022 and Provides Corporate Update Poxel SA, a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced its cash position and revenue and provided a corporate update for the twelve months…
IPF Partners Announces up to €20m Financing to Elder to Fund Expansion Elder, the UK’s leading digital elderly care marketplace, today announced that it has secured up to €24 million in debt and equity financing from IPF Partners – a leading alternative financing provider focused on the healthcare sector – alongside existing investors Acton Capital…